<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887676</url>
  </required_header>
  <id_info>
    <org_study_id>ARB-05-2018</org_study_id>
    <nct_id>NCT03887676</nct_id>
  </id_info>
  <brief_title>Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA)</brief_title>
  <acronym>ARBA</acronym>
  <official_title>A Randomized Placebo-controlled Trial of ARBaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evdokia Anagnostou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Holland Bloorview Kids Rehabilitation Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Anagnostou, Evdokia, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and efficacy of arbaclofen vs. placebo on social function&#xD;
      in children and adolescents with Autism Spectrum Disorder (ASD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no pharmacologic treatments available for social function deficits in individuals&#xD;
      with ASD. The data for pharmacologic treatment of repetitive behaviours in this disorder has&#xD;
      also become difficult to interpret given that the last two large multisite trials of&#xD;
      selective serotonin reuptake inhibitors (SSRIs) in autism are reported to be negative for the&#xD;
      treatment of repetitive behaviours. Only the associated symptom of irritability has 2 drugs&#xD;
      with Food and Drug Administration (FDA) indications, whereas no systematic data exists on the&#xD;
      pharmacologic treatment of anxiety in ASD, and response to rates to stimulants for&#xD;
      hyperactivity are lower than what is seen in Attention Deficit Hyperactivity Disorder (ADHD).&#xD;
      In addition, there are no biological markers of treatment response identified in this&#xD;
      population at this point. This study will examine the potential efficacy and safety of&#xD;
      arbaclofen for social function, and will explore biological markers of safety and treatment&#xD;
      response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Anticipated">May 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) - Social Domain</measure>
    <time_frame>16 weeks</time_frame>
    <description>To examine the effect of arbaclofen vs. placebo social function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions - Impression Scale - Improvement (CGI-I)</measure>
    <time_frame>16 weeks</time_frame>
    <description>To examine the effect of arbaclofen vs. placebo on measures of global function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aberrant Behavior Checklist (ABC) - Social Withdrawal Subscale</measure>
    <time_frame>16 weeks</time_frame>
    <description>To examine the effect of arbaclofen vs. placebo on social withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) - Communication Domain</measure>
    <time_frame>16 weeks</time_frame>
    <description>To examine the effect of arbaclofen vs. placebo on communication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Monitoring Uniform Report Form (SMURF)</measure>
    <time_frame>16 weeks</time_frame>
    <description>To examine the safety and tolerability of arbaclofen in children and adolescents with ASD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions - Impression Scale - Global (CGI-I-Global)</measure>
    <time_frame>16 weeks</time_frame>
    <description>To examine the safety and tolerability of arbaclofen in children and adolescents with ASD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD)</measure>
    <time_frame>16 weeks</time_frame>
    <description>To examine the safety and tolerability of arbaclofen in children and adolescents with ASD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidality assessment using the Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>16 weeks</time_frame>
    <description>To examine the safety and tolerability of arbaclofen in children and adolescents with ASD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Arbaclofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbaclofen</intervention_name>
    <description>Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg</description>
    <arm_group_label>Arbaclofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally as disintegrating tabs, round, white and beveled edges</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatients 5-17 years of age inclusive.&#xD;
&#xD;
          2. Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).&#xD;
             DSM-5 criteria will be established by a clinician with expertise with individuals with&#xD;
             ASD. Diagnosis will be supported by the Autism Diagnostic Observation Schedule, Second&#xD;
             Edition (ADOS-2).&#xD;
&#xD;
          3. Complex language to qualify for ADOS-2 modules 3 or 4.&#xD;
&#xD;
          4. If already receiving stable concomitant medications affecting behaviour, have stable&#xD;
             regimens with no changes during the preceding 6 weeks prior to Screening, and will not&#xD;
             electively initiate new or modify ongoing medications for the duration of the study.&#xD;
&#xD;
          5. If already receiving stable non-pharmacological educational and behavioural&#xD;
             interventions, have continuous participation during the preceding 3 months prior to&#xD;
             Screening, and will not electively initiate new or modify ongoing interventions for&#xD;
             the duration of the study.&#xD;
&#xD;
          6. Have normal physical examination and laboratory test results at Screening. If&#xD;
             abnormal, the finding(s) must be deemed clinically insignificant by the Investigator.&#xD;
&#xD;
          7. Ability to obtain written informed consent from the participant, if developmentally&#xD;
             appropriate. If a participant does not have the capacity to consent, ability to obtain&#xD;
             assent (if developmentally appropriate), as well as written informed consent from&#xD;
             their parent(s)/legal guardian(s).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant females; sexually active females on inadequate birth control.&#xD;
&#xD;
          2. Have a serious medical condition that, based on Investigator judgment, might interfere&#xD;
             with the conduct of the study, confound interpretation of the study results, or&#xD;
             endanger their own well-being. Have evidence of any significant hematological,&#xD;
             endocrine, cardiovascular (including uncorrected symptomatic congenital heart&#xD;
             disease), respiratory, renal, hepatic, or gastrointestinal disease, not including mild&#xD;
             common pediatric diseases in these areas that are stable (e.g. mild asthma,&#xD;
             constipation, etc.).&#xD;
&#xD;
          3. Have unstable epilepsy (i.e. seizures occurring within the last 6 months), or have&#xD;
             epilepsy and not on stable doses of antiepileptic medications (i.e. dose changes&#xD;
             within the last 3 months).&#xD;
&#xD;
          4. Have a history of drug abuse.&#xD;
&#xD;
          5. Have hypersensitivity to arbaclofen or any components of its formulation.&#xD;
&#xD;
          6. Unable to tolerate venipuncture procedures for blood sampling.&#xD;
&#xD;
          7. Actively enrolled in another intervention study.&#xD;
&#xD;
          8. Taking racemic bacblofen, vigabatrin, tiagapine, riluzole, clobazam or regular&#xD;
             benzodiazepine use (prn and hs use is allowed).&#xD;
&#xD;
          9. Unable to take oral medications.&#xD;
&#xD;
         10. Known hypersensitivity to racemic baclofen.&#xD;
&#xD;
         11. Inability to speak and understand English sufficiently enough to allow for the&#xD;
             completion of all study assessments (parent/legal guardian; participant).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evdokia Anagnostou, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holland Bloorview Kids Rehabilitation Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Nicolson, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Lawson Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia Frei, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University, Offord Centre for Child Studies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muhammad Ayub, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Genore</last_name>
    <phone>416-425-6220</phone>
    <phone_ext>6443</phone_ext>
    <email>LGenore@hollandbloorview.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>McMaster University, Offord Centre for Child Studies</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Frei, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Universtiy</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7M 8A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muhammad Ayub, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Western Ontario, Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Nicolson, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holland Bloorview Kids Rehabilitation Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evokdia Anagnostou, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Anagnostou, Evdokia, M.D.</investigator_affiliation>
    <investigator_full_name>Evdokia Anagnostou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ASD</keyword>
  <keyword>Autism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

